ELTX
Elicio Therapeutics Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer. by combining expertise in materials science and immunology, elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. the elicio amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body’s own system of defenses, to defeat cancer and stop its recurrence. this substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. elicio's lead amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. elicio was founded to expand and apply the ground-breaking amphiphile technology invented and developed in the labs of darrell
Market Cap: 34.8 Million
Primary Exchange: NASDAQ
Shares Outstanding: 8.41 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 209 trading days
From: 2023-06-01 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|